"The increasing expenses associated with bladder cancer treatment highlight wider issues regarding the sustainability of health care expenditures in the US," writes Michael S. Cookson, MD, MMHC, FACS.

Sasanlimab combined with BCG significantly improved event-free survival in BCG-naïve, high-risk NMIBC patients compared to BCG alone. The CREST trial's results suggest potential paradigm shifts in ...

“As long as APPs are properly supported, they will take off and they will change your practice,” says Mark T. Edney, MD. In this video, Mark T. Edney, MD, discusses how to foster a collaborative ...

TYRA-300's phase 2 trial in NMIBC aims to evaluate safety and efficacy, enrolling up to 90 patients with FGFR3 alterations. The primary endpoint is the complete response rate at 3 months, with ...

A panelist discusses how emerging investigational agents for NMIBC show promise through diverse mechanisms, including oncolytic viruses (CG0070), immune checkpoint inhibitors (durvalumab, sasanlimab), ...

"Studying the microbiome overall is challenging because it's dirty science. You have to be incredibly careful with contamination," says Ilaha Isali, MD, MSc, and Laura Bukavina, MD, MPH, MSc. Isali: ...

“Another aspect is how to make this more and more complex diagnostic chain for prostate cancer work in practice, because we now have so [many] more tools than we had a decade ago,” says Tobias ...

9MW2821 combined with toripalimab received breakthrough therapy designation for advanced urothelial carcinoma, enhancing development and review processes. Initial study results showed an 87.5% ...

VIR-5500 demonstrated promising PSA response in mCRPC patients, with 58% achieving at least a 50% reduction in PSA levels. No dose-limiting toxicities were observed, and treatment-emergent adverse ...